Outpatient radioiodine therapy for thyroid cancer: A safe nuclear medicine procedure

Clinical Nuclear Medicine

Volumn 36, Issue 6, 2011, Pages 440-445

  Willegaignon, José ^a   Sapienza, Marcelo ^a   Ono, Carla ^a   Watanabe, Tomoco ^a   Guimarães, Maria Inês ^a   Gutterres, Ricardo ^b   Marechal, Maria Helena ^b   Buchpiguel, Carlos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

dosimetry; I 131 therapy; outpatient treatment; radiation protection; radiologic impact; thyroid cancer

Indexed keywords

ANTIEMETIC AGENT; IODINE 131;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CAREGIVER; CONTROLLED STUDY; DOSIMETRY; DRUG EXCRETION; DRUG UPTAKE; FAMILY HEALTH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTPATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; RADIATION DOSE; RADIATION PROTECTION; RADIATION SAFETY; RADIOACTIVE CONTAMINATION; RADIOACTIVITY; SOLID WASTE; STOMACH ACID SECRETION; THERMOLUMINESCENCE DOSIMETER; THYROID CANCER; TREATMENT INDICATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NUCLEAR MEDICINE; RADIOTHERAPY DOSAGE; SAFETY; THYROID NEOPLASMS; YOUNG ADULT;

EID: 79955862530     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182184fa0     Document Type: Article

References (45)

1. Lubin E. Definitive improvement in the approach to the treated patient as a radioactive source. J Nucl Med. 2002;43:364-365. (Pubitemid 34208098)
2. 131I therapy: inpatient or outpatient? J Nucl Med. 2000;41:1876-1878.
3. International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. ICRP Publication 94. Oxford, United Kingdom: Pergamon Press; 2004.
4. International Atomic Energy Agency. Release of patients after radionuclide therapy. Safety Report Series No. 63. Vienna, Austria: IAEA; 2009.
5. National Council on Radiation Protection and Measurements. Management of radionuclide therapy patients. Report No. 155. Bethesda, MD: NCRP; 2006.
6. 131I)NaI, on an outpatient basis, be safe? Nucl Med Commun. 2009;30:533-5461.
7. Comissão Nacional de Energia Nuclear. Gerência de rejeitos radioativos em instalações radiativas. Norma 6.05. Brazil: CNEN; 1985.
8. International Atomic Energy Agency. Application of the concepts of exclusion, exemption and clearance. Safety Standards Series No. RS-G-1.7. Vienna, Austria: IAEA; 2004.
9. 131I-tositumomab therapy. J Nucl Med. 2002;43:354-363. (Pubitemid 34208097)
10. International Atomic Energy Agency. Radiological protection for medical exposure to ionizing radiation. Safety Guide No. RS-G-1.5. Vienna, Austria: IAEA; 2002.
11. International Atomic Energy Agency. International basic safety standards for protection against ionizing radiation and for the safety of radiation sources. Safety Series No. 115. Vienna, Austria: IAEA; 1996.
12. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Oxford, United Kingdom: Pergamon Press; 1991.
13. International Commission on Radiological Protection. Radiological protection and safety in medicine. ICRP Publication 73. Oxford, United Kingdom: Pergamon Press; 1996.
14. Comissão Nacional de Energia Nuclear. Diretrizes básicas de proteção radi-ológica. Norma 3.01. Brazil: CNEN; 2005.
15. 131I) treatment of hyperthyroidism: radiation protection and quality assurance. Eur J Nucl Med. 1999;26:683-685. (Pubitemid 29338654)
16. 131I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001; 42:907-915. (Pubitemid 32537438)
17. Cappelen T, Unhjem JF, Amundsen AL, et al. Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131. Eur J Nucl Med Mol Imaging. 2006;33:81-86. (Pubitemid 41785313)
18. 131I) therapy for thyroid carcinoma. JAMA. 2000;283: 2272-2274. (Pubitemid 30246779)
19. 131I. Radiat Prot Dosimetry. 2006;118:22-27. (Pubitemid 43786724)
20. 131I for hyperthyroidism. Med Phys. 2004;31:3194-3200. (Pubitemid 40064971)
21. Pant GS. Dosimetric and radiation safety considerations in radioiodine therapy. Ind J Nucl Med. 2005;20:1-3.
22. Ibis E, Wilson CR, Collier BD, et al. Iodine-131 contamination from thyroid cancer patient. J Nucl Med. 1992;33:2110-2115.
23. 131I clearance in thyroid cancer therapy. Health Phys. 2006;91:123-127. (Pubitemid 44086652)
24. International Atomic Energy Agency. Release of sites from regulatory control on termination of practices. Safety Guide No. WS-G-5.1. Vienna, Austria: IAEA; 2006.
25. International Atomic Energy Agency. Clearance levels for radionuclides in solid materials: application exemption principles. TECDOC-855. Vienna, Austria: IAEA; 1996.
26. International Atomic Energy Agency. Radiological aspects of non-fixed contamination of packages and conveyances. TECDOC-1449. Vienna, Austria: IAEA; 2005.
27. Hamby DM, Benke RR. Uncertainty of the iodine-131 ingestion dose conversion factor. Radiat Prot Dosimetry. 1999;82:245-256. (Pubitemid 29319823)
28. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. UNSCEAR 2000. New York, NY: UNSCEAR; 2000.
29. Martin JE, Fenner FD. Radioactivity in municipal sewage and sludge. Public Health Rep. 1997;112:308-316. (Pubitemid 27328271)
30. Prichard HM, Gesell TF, Davis E. Iodine-131 levels in sludge and treated municipal wastewaters near a large medical complex. Am J Public Health. 1981;71:47-52. (Pubitemid 11207806)
31. Larsen IL, Stetar EA, Giles BG, et al. Concentration of iodine-131 released from a hospital into a municipal sewer. RSO Mag. 2001;6:13-18.
32. 131I) iodobenzylguani-dine (MIBG) in municipal sewerage. Health Phys. 1997;73:333-339.
33. Washington State Department of Health. The presence of radionuclides in sewage sludge and their effect on human health. WDOH/320-013. Available at: http://www.doh.wa.gov/ehp/rp/environmental. Accessed August 13, 2008.
34. Siegel JA, Sparks RB. Radioactivity appearing at landfills in household trash of nuclear medicine patients: much ado about nothing? Health Phys. 2002; 82:367-372. (Pubitemid 34157536)
35. Marcus CS, Aldrich R. Avoiding solid waste contamination problems from iodine-131 patients. J Nucl Med. 1997;38:26N.
36. Marriot CJ, Weber CE, Gulenchyn KY. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy. Radiat Prot Dosimetry. 2007;123:62-67.
37. Mountford PJ, O'Doherty MJ. Exposure of critical groups to nuclear medicine patients. Appl Radiat Isot. 1999;50:89-111. (Pubitemid 29048993)
38. 131I radiation exposure. J Nucl Med. 2008;49:691-693. (Pubitemid 351717531)
39. Aurengo A. Chernobyl: the effects on public health? Physics and Society. 2002. Available at: http://units.aps.org/units/fps/newsletters/2002/october/ index.cfm. Accessed August 13, 2008.
40. González AJ. Regulation of low-level radiation. C R Acad Sci III. 1999;322: 241-243.
41. Health Physics Society. Radiation risk in perspective. Position Statement of the Health Physics Society. 2004. Available at: http://www.hps.org/ documents/ radiationrisk.pdf. Accessed August 13, 2008.
42. American Nuclear Society. Health effects of low-level radiation. Position Statement 41; 2001. Available at: http://www.ans.org/pi/ps/docs/ps41.pdf. Accessed August 13, 2008.
43. U.S. Nuclear Regulatory Commission. Instruction concerning risks from occupational radiation exposure. Regulatory Guide 8.29. Washington, DC: US NRC; 1996.
44. Rockwell T. The realism project: it's time to get real. Nucl News. 2004;47: 10-12. (Pubitemid 40025916)
45. Mehta SC. Health risks of low level radiation exposures: a review. Ind J Nucl Med. 2005;20:29-41.